质子泵抑制剂

识别有食管损伤可能性的高危患者对这些接受内窥镜检查或者服用质子泵抑制剂治疗的患者的随访和治疗有重要意义。

Identifying high-risk patients for esophageal injury potentially has an impact on follow-up or treatment of these individuals by endoscopy or prophylactic proton pump inhibitor treatment .

生长抑素和质子泵抑制剂联合应用预防ERCP术后胰腺炎

Prevention of acute pancreatitis induced by ERCP with the union between somatostatin and proton pump inhibitor

检测HP前2个月均停用各种抗生素及H2受体阻滞剂或质子泵抑制剂。

The antibiotics and H receptor blockage were stopped before 2 months .

质子泵抑制剂和H2受体阻滞剂类药物预防脑卒中后应激性溃疡出血的系统评价

Proton Pump Inhibitor and H_2RA Pharmacological Prevention of Stress Ulcer Bleeding in Stroke Patients : A Systematic Review of Randomized Controlled Trials

患者表现出受pH值与胃食管反流症状的研究或手术后应被视为与质子泵抑制剂的长期逆流。

Patients with demonstrated reflux by pH study or with reflux symptoms after surgery should be treated long-term with proton pump inhibitors .

质子泵抑制剂盘托拉唑对大鼠肝药酶中P450的影响

Effect of Proton Pump Inhibitor-Pantoprazole on P450 in Rat Liver Microsomes

FDA评估报告显示低镁血症相关的不良事件和长期使用质子泵抑制剂有关。

The FDA review suggests an association between hypomagnesemia-related serious adverse events and prolonged PPI use .

抗酸治疗经历了碱性药物、H2受体拮抗剂、质子泵抑制剂的不断发展。

Antacid therapies have gone through alkaline drugs , H2 receptor antagonist , proton pump inhibitors .

目的探讨抑酸药H2受体拮抗剂与质子泵抑制剂（PPI）对消化性溃疡并出血的疗效。

Objective To study the effect of H2-receptor antagonists and proton-pump inhibitors on peptic ulcer bleeding .

目的系统评价质子泵抑制剂（PPI）与H2受体阻滞剂（H2RA）预防脑卒中后应激性溃疡出血的临床疗效及安全性。

Objective To assess the clinical efficacy and safety of proton pump inhibitor ( PPI ) and H_2RA for stress ulcer bleeding in stroke patients .

耐信是质子泵抑制剂（PPI）奥美拉唑的一种异构体。

Nexium is part of a class of drugs known as proton pump inhibitors ( PPIs ) .

FDA相信非处方药类质子泵抑制剂如果按照其标签上标注的用法使用，引发低镁血症的风险很低。

FDA believes that there is very little risk of hypomagnesemia when OTC PPIs are used according to the directions on the OTC label .

结论静脉使用质子泵抑制剂的抑酸效果明显优于H2受体拮抗剂，尤其是奥美拉唑静脉滴注胃内pH提高持续的时间较长。

Conclusion Intravenous use of omeprazole in active duodenal ulcer bleeding is superior to H 2 receptor antagonists , the increase of intragastric pH maintains for a longer period .

目的系统性评价左氧氟沙星和质子泵抑制剂（PPI）三联疗法治疗幽门螺杆菌（HP）的疗效和不良反应发生率。

Objective To systematically assess the effectiveness and adverse reaction rates of levofloxacin PPI triple therapy in the treatment of Helicobacter pylori ( HP ) .

目的研究鼠胃黏膜壁细胞对H2受体拮抗剂和质子泵抑制剂的耐受性（脱敏）。

Objective To explore the tolerance ( desensitization ) of the rat gastric parietal cell induced by histamine H_2 receptor antagonist and proton pump inhibitor .

背景：阿司匹林及氯吡格雷联合抗血小板治疗在世界范围内广泛运用，而质子泵抑制剂（PPI）包括埃索美拉唑及泮托拉唑是临床上最常用于防止胃肠道出血的药物之一。

Background : Aspirin-clopidogrel antiplatelet dual therapy is prescribed worldwide , with PPIs included esomeprazole and pantoprazole were frequently associated to prevent gastrointestinal bleeding .

结论H2受体拮抗剂能够诱导壁细胞H2受体出现脱敏，质子泵抑制剂未出现耐受现象。

Conclusion : H_2 receptor antagonists induce the desensitization of the H2 receptor on the the rat gastric parietal cell , but proton pump inhibitors do not have tolerance .

但加服H2受体阻滞剂或质子泵抑制剂等抑酸制剂并不能预防或减少溃疡病复发和上消化道出血。

However , H2 blocker or add services proton pump inhibitors and other acid-suppressing agents can not prevent or reduce the recurrence of ulcer disease and upper gastrointestinal blood .

目的：研究不含甲硝唑的短程低剂量质子泵抑制剂（PPI）三联疗法对幽门螺杆菌（HP）根除消化性溃疡愈合的疗效。

Objective : To evaluate the efficacy of a new short term , low dose triple therapy without metronidazole for eradication of H. pylori and recovery of H.pylori correlative peptic ulcer .

年龄≥65岁、糖尿病、吸烟史、吞咽障碍、低蛋白血症、预防性应用抗生素、脱水剂、H2受体阻滞剂或质子泵抑制剂、鼻饲治疗是SAP的危险因素。

The risk factors of SAP include age ≥ 65 , diabetes , smoking , dysphagia , hypoproteinemia , antibiotic prophylaxis , dehydrant , H2-blocker or inhibitors of proton pump , nasal feeding .

目的评价胃食管反流病（GERD）诊断方法及质子泵抑制剂（PPI）治疗试验的价值。

Objective To evaluate the role of acid inhibition therapeutic test with proton pump inhibitors ( PPI ) in the diagnosis of gastroesophageal reflux disease ( GERD ) .

短期静脉应用质子泵抑制剂与氯吡格雷合用未增加急性心肌梗死PCI术患者院内发生主要不良心血管事件的风险以及出院后30天内因ACS再入院率。

The combination of the short-term intravenous proton pump inhibitors and clopidogrel does not increase the risk of recent major adverse cardiovascular events and rehospitalization rate of the patients with acute myocardial infarction . 3 .

研究表明，三个质子泵抑制剂对其它经CYP系列代谢的药物皆表现出较弱的相互作用，少数文献报道这一相互作用无临床相关性，并且未发现剂量与不良反应的相关性。

Some of the research reported that there was not relative in clinic , also there was no relative with dose and side effect .

一项涉及近300万人的数据的分析显示，目前广泛用于预防胃反流的药物——质子泵抑制剂（protonpumpinhibitors，P.P.I.，如奥美拉唑和兰索拉唑等）可能会增加心肌梗死的风险。

The widely used drugs known as proton pump inhibitors , or P.P.I. 's - gastric reflux preventives like Prilosec and Prevacid - may increase the risk for heart attack , according to analysis of data involving almost three million people .

处方质子泵抑制剂用于治疗的疾病如反流性胃食管疾病（GERD）、胃和小肠溃疡、食道炎症。

Prescription proton pump inhibitors are used to treat conditions such as gastroesophageal reflux disease ( GERD ), stomach and small intestine ulcers , and inflammation of the esophagus .

背景：在功能性消化不良（FD）患者中，以铋剂为基础的治疗方案根除幽门螺杆菌（H.pylori）的疗效优于以质子泵抑制剂（PPI）为基础的治疗方案。

Bismuth-based treatment regimens are preferable to proton pump inhibitors ( PPI ) - based ones in eradication of Helicobacter pylori ( H. pylori ) in patients with functional dyspepsia ( FD ) .

方法选择2004年3月至2005年1月经胃镜检查、病理证实的15例BE患者进行60WAPC治疗，术后予质子泵抑制剂辅助治疗。

Methods 15 patients with histologically proven BE , selected from Renji Hospital from May 2004 to January 2005 , underwent 60W APC were prospectively analyzed .

1周或2周的含铋剂、质子泵抑制剂或雷尼替丁胶体铋（RBC）三联疗法是公认的较好方案，Hp根除率为80%～90%，1周和2周治疗根除率无明显差异。

One or two weeks ' triple-therapy including bismuth citrate , proton-pump inhibitor or RBC is the best program , with the eradication rate varying from 80 % ~ 90 % and no significant difference as to one or two week .

质子泵抑制剂（PPI）广泛应用于非甾体抗炎药（NSAIDs）相关胃肠疾病的治疗，但其疗效缺乏相关循证医学资料证实。

Background : Proton pump inhibitors ( PPI ) are widely used in the treatment of non-steroidal anti-inflammatory drugs ( NSAIDs ) - associated gastrointestinal diseases , but corresponding evidence-based information is scarce .

自第一个质子泵抑制剂（PPI）奥美拉唑于1988年上市以来，PPI已成为酸相关性疾病治疗的首选药物。

Since the first proton pump inhibitor ( Omeprazole ) came into the market in1988 , PPIs have been considered as the drugs of first choice for treatment of patients with various acid-related diseases .